Rapport Therapeutics (RAPP) said Thursday that preliminary analysis of data from positron emission tomography and the second multiple ascending dose trials for RAP-219 showed it achieved target receptor occupancy within five days of dosing.
The investigational drug also maintained a differentiated tolerability profile, according to the company.
The company is evaluating RAP-219 in patients with refractory focal epilepsy in a phase 2a proof-of-concept trial and expects topline results in mid-2025.
Price: 16.69, Change: -1.10, Percent Change: -6.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.